Observational 6-month Open-label Study of Japanese Type 2 Diabetes Patients Switching from NPH Insulin to Insulin Detemir in Basal–Bolus Regimen: 23rd Article of the Japan Diabetes Clinical Data Management Study Group (JDDM23)

Author： Oishi M   Abe N   Yokoyama H   Kuribayashi N   Tomonaga O   Matoba K   Kobayashi M  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.40, Iss.2, 2012-03, pp. : 787-797

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

By Rašlová Katarina  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 279-285

Adis International

Access to resources Recommend Favorite

Influence of BMI, Age and Duration of Diabetes Mellitus on Glycaemic Control with Twice-Daily Injections of Biphasic Insulin Aspart 30 versus Multiple Daily Injections of Insulin Aspart (JDDM 18): Retrospective Reanalysis of a 6-Month, Randomized, Open-Label, Multicentre Trial in Japan

By Arai K.  

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 35-40

Adis International

Access to resources Recommend Favorite

Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus: A Preliminary, Observational, Open-Label Study

By Kawai Toshihide   Takei Izumi   Shimada Akira  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 237-245

Adis International

Access to resources Recommend Favorite

Insulin detemir weighs in against insulin glargine in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Deleterious Outcomes after Abrupt Transition from Insulin Glargine to Insulin Detemir in Patients with Type 1 Diabetes Mellitus

By Kabadi Udaya M.  

Clinical Drug Investigation, Vol. 28, Iss. 11, 2008-01 ,pp. : 697-701

Adis International

Access to resources Recommend Favorite